Successful long-term management of refractory cutaneous and upper airway sarcoidosis with periodic infliximab infusion.

Abstract

A clinically refractory case of cutaneous sarcoidosis was successfully treated with infliximab infusion therapy at a dose of 5mg/kg. Skin lesions cleared dramatically and remain resolved during a 3(1/2) year follow-up, the longest follow-up reported to date. Ongoing biological drug therapy has been administered at a frequency of every 8-10 weeks. Despite cost and safety concerns, infliximab should be considered in cases of cutaneous sarcoidosis refractory to standard treatment protocols.

• Authors: Ted Rosen, Christy Doherty
• Journal: Dermatology online journal (Dermatol Online J) Vol. 13 Issue 3 Pg. 14 (Jul 13 2007) ISSN: 1087-2108 [Electronic] United States
• PMID: 18328208 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Dermatologic Agents
• Tumor Necrosis Factor-alpha
• Infliximab

Topics

• Antibodies, Monoclonal (administration & dosage)
• Biopsy
• Dermatologic Agents (administration & dosage)
• Diagnosis, Differential
• Drug Administration Schedule
• Female
• Follow-Up Studies
• Humans
• Infliximab
• Infusions, Intravenous
• Middle Aged
• Nose Diseases (drug therapy, pathology)
• Sarcoidosis (drug therapy, pathology)
• Skin Diseases (drug therapy, pathology)
• Time Factors
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)